Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Despite crowding in the next-gen weight loss space, Metsera has raised over $500 million since its April launch, indicating a ...

So far this year, Eli Lilly (NYSE: LLY) has been on an absolute tear and is swiftly becoming the world's most prolific ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

MSF calls for insulin manufacturers to provide $1 injection pens globally, emphasizing current high prices and limited access ...

Amgen is testing MariTide as a once-monthly shot, making it a promising potential rival to the weekly blockbuster weight-loss injections from Novo Nordisk and Eli Lilly. Tuesday's stock decline lopped ...

Ozempic: Novo Nordisk’s name-brand version of injectable semaglutide ... the first and only GIP and GLP-1 receptor agonist ...